Johnson & Johnson (J&J; New Brunswick, New Jersey) turned the med-tech landscape on its ear Tuesday, as it said it plans to cut as many as 8,000 jobs across the world and to end its recently announced collaboration with Pfizer (New York) to develop a treatment for Alzheimer's disease.

(Medical Device Daily)